Merida Biosciences, Inc. is a biotechnology company specializing in the development of precision therapeutics for autoimmune and allergic diseases. The company focuses on a novel platform that enables the selective and durable elimination of pathogenic autoantibodies, which are the root causes of various antibody-driven conditions, while preserving normal immune function.
Headquartered in Cambridge, Massachusetts, Merida was founded in 2022 and publicly launched in April 2025 following a $121 million Series A financing round led by Bain Capital Life Sciences, BVF Partners, and Third Rock Ventures. Its lead candidate, MER511, is in Phase 1 clinical development for Graves’ disease and thyroid eye disease. Additional programs include MER769, a preclinical asset targeting IgE-mediated allergic diseases such as food allergy, asthma, and chronic spontaneous urticaria, as well as earlier-stage efforts in kidney diseases like primary membranous nephropathy.
The company’s approach represents an advancement in immunology by addressing the underlying biology of these diseases rather than broadly suppressing the immune system. In August 2026, Eli Lilly and Company announced an agreement to acquire Merida for up to $2.875 billion in cash, with the transaction expected to close in the fourth quarter of 2026, integrating Merida’s platform and pipeline into Lilly’s immunology portfolio.
None yet. When a new project in the record names Merida Biosciences as owner, partner or investor, it shows here.
Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.
